1
Country: France | Funding: $278M
Tissium develops fully biosynthetic programmable polymers designed for atraumatic tissue repair and reconstruction. The company's portfolio includes one commercial product and six products in development in three areas: sutureless nerve repair, hernia repair, and cardiovascular sealants. The company's flagship product, COAPTIUM CONNECT, is designed for sutureless peripheral nerve repair. It is indicated for sutureless repair of unconnected peripheral nerve injuries where a gap of 1 centimeter or less exists or can be closed by flexing the limb. It allows surgeons to reconnect severed nerve ends without placing tiny sutures through the nerve.
Tissium develops fully biosynthetic programmable polymers designed for atraumatic tissue repair and reconstruction. The company's portfolio includes one commercial product and six products in development in three areas: sutureless nerve repair, hernia repair, and cardiovascular sealants. The company's flagship product, COAPTIUM CONNECT, is designed for sutureless peripheral nerve repair. It is indicated for sutureless repair of unconnected peripheral nerve injuries where a gap of 1 centimeter or less exists or can be closed by flexing the limb. It allows surgeons to reconnect severed nerve ends without placing tiny sutures through the nerve.
2
Country: France | Funding: €258.1M
The mission of every team member at Carmat is to contribute to the development of innovative artificial organs – the artificial heart today, tomorrow other vital organs – to treat millions of patients affected by advanced disease of these organs and to restore their normal life. Liquidated
The mission of every team member at Carmat is to contribute to the development of innovative artificial organs – the artificial heart today, tomorrow other vital organs – to treat millions of patients affected by advanced disease of these organs and to restore their normal life. Liquidated
3
Country: USA | Funding: $117.5M
At Organovo, we design and create functional human tissues using our proprietary three-dimensional bioprinting technology. Our goal is to build living human tissues that are proven to function like native tissues. With reproducible 3D tissues that accurately represent human biology, we are enabling ground-breaking therapies by:
At Organovo, we design and create functional human tissues using our proprietary three-dimensional bioprinting technology. Our goal is to build living human tissues that are proven to function like native tissues. With reproducible 3D tissues that accurately represent human biology, we are enabling ground-breaking therapies by:
4
Country: USA | Funding: $101.5M
Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. Its platform will enable engineered whole cells (called "satellites") to be implanted into patients to repair or even replace damaged organ tissue.
Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. Its platform will enable engineered whole cells (called "satellites") to be implanted into patients to repair or even replace damaged organ tissue.
5
Country: USA | Funding: $39.4M
SynCardia Systems is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart.
SynCardia Systems is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart.
6
Country: USA | Funding: $80M
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
7
Country: USA | Funding: $79.4M
Prellis employs holographic tissue printing technology with rapid fully human antibody discovery, in vitro human disease and ADME/Tox models
Prellis employs holographic tissue printing technology with rapid fully human antibody discovery, in vitro human disease and ADME/Tox models
8
Country: USA | Funding: $53M
BiVACOR is a privately held company founded in 2008. Our staff includes world-class engineers, medical specialists, and business executives, who are diligently working to advance this ground-breaking technology. Together, we have established a strong collaborative network that extends both nationally and internationally. Our world headquarters is located in Houston, Texas, USA, and our international office is in Brisbane, Australia.
BiVACOR is a privately held company founded in 2008. Our staff includes world-class engineers, medical specialists, and business executives, who are diligently working to advance this ground-breaking technology. Together, we have established a strong collaborative network that extends both nationally and internationally. Our world headquarters is located in Houston, Texas, USA, and our international office is in Brisbane, Australia.
9
Country: Japan | Funding: $29.8M
We contribute to significant advances in medical treatments through our revolutionary 3D tissue-engineering technology. We successfully developed the BIO 3D PRINTER, Regenova. It is a state-of-the-art robotic system that enables fully automated fabrication of three-dimensional artificial tissues/organs from living cells.
We contribute to significant advances in medical treatments through our revolutionary 3D tissue-engineering technology. We successfully developed the BIO 3D PRINTER, Regenova. It is a state-of-the-art robotic system that enables fully automated fabrication of three-dimensional artificial tissues/organs from living cells.
10
Country: India | Funding: $24.6M
Pandorum Technologies is a biotechnology startup with a distinct synergy of life science and engineering competences focused on tissue engineering. The company uses its proprietary technology platforms to design and manufacture functional, three-dimensional living human tissues; intended for medical research, therapeutic and other applications.
Pandorum Technologies is a biotechnology startup with a distinct synergy of life science and engineering competences focused on tissue engineering. The company uses its proprietary technology platforms to design and manufacture functional, three-dimensional living human tissues; intended for medical research, therapeutic and other applications.
11
Country: USA | Funding: $17.2M
Stämm is downsizing a whole biotech facility into an all-in-one, pug-n-play desktop unit called The Bioprocessor.
Stämm is downsizing a whole biotech facility into an all-in-one, pug-n-play desktop unit called The Bioprocessor.
12
Country: USA | Funding: $6.7M
BioAesthetics is regenerating the nipple-areolar complex for the 200,000+ women whom undergo mastectomies every year.
BioAesthetics is regenerating the nipple-areolar complex for the 200,000+ women whom undergo mastectomies every year.
13
Country: USA | Funding: $4.6M
Nanofiber Solutions designs and manufactures novel three-dimensional (3D) nanofiber scaffolds. Our platform technology mimics the extracellular matrix found within the body, providing a realistic environment for for all types of cells whether in the body or on a lab bench.
Nanofiber Solutions designs and manufactures novel three-dimensional (3D) nanofiber scaffolds. Our platform technology mimics the extracellular matrix found within the body, providing a realistic environment for for all types of cells whether in the body or on a lab bench.
14
Country: China | Funding: CN¥33M
Chinese company, founded in 2013. Commercializing bioprinter “Regenovo” for “making biomaterials, organs and tissues” for regenerative medicine.
Chinese company, founded in 2013. Commercializing bioprinter “Regenovo” for “making biomaterials, organs and tissues” for regenerative medicine.
15
Country: Singapore
Cornea Biosciences was founded in 2011 with the express objective of furthering development of the bioengineered cornea, and providing this cornea to the millions of people unilaterally or bilaterally blind from corneal disease or injury and unable to obtain a corneal transplant due to a severe shortage of human donor corneas. The company’s cornea is the result of ten years of research and development conducted at the University of Ottawa in Canada and Linkoping University in Sweden.
Cornea Biosciences was founded in 2011 with the express objective of furthering development of the bioengineered cornea, and providing this cornea to the millions of people unilaterally or bilaterally blind from corneal disease or injury and unable to obtain a corneal transplant due to a severe shortage of human donor corneas. The company’s cornea is the result of ten years of research and development conducted at the University of Ottawa in Canada and Linkoping University in Sweden.
